You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

edp-938

Showing 1 - 10 of 10
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Respiratory Syncytial Virus (RSV) Trial in Madison (EDP-938)

Completed
  • Respiratory Syncytial Virus (RSV)
  • EDP-938
  • Madison, Wisconsin
    Covance Clinical Research Unit
Mar 21, 2022

RSV Infection Trial in Lenexa (EDP-938, Tacrolimus, Dabigatran)

Completed
  • RSV Infection
  • EDP-938
  • +4 more
  • Lenexa, Kansas
    Pharmaceutical Research Associates, Inc.,
Oct 12, 2021

RSV Infection Trial in United States (EDP-938, Placebo)

Recruiting
  • RSV Infection
  • EDP-938
  • Placebo
  • Westlake, California
  • +13 more
Dec 2, 2022

RSV Infection Trial in Salt Lake City (EDP-938, Fluconazole)

Completed
  • RSV Infection
  • Salt Lake City, Utah
    Pharmaceutical Research Associates, Inc.,
Apr 29, 2021

Respiratory Syncytial Virus (RSV) Trial in Worldwide (EDP-938, Placebo)

Recruiting
  • Respiratory Syncytial Virus (RSV)
  • EDP-938
  • Placebo
  • Long Beach, California
  • +62 more
Oct 9, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (EDP-938, Placebo)

Recruiting
  • Respiratory Syncytial Virus Infections
  • EDP-938
  • Placebo
  • Augusta, Georgia
  • +59 more
May 27, 2022

Respiratory Syncytial Virus Trial in Worldwide (EDP-938, Placebo)

Completed
  • Respiratory Syncytial Virus
  • EDP-938
  • Placebo
  • Birmingham, Alabama
  • +106 more
Feb 9, 2022

RSV Infection Trial in Lenexa (EDP-938, Itraconazole, Rifampin)

Completed
  • RSV Infection
  • EDP-938
  • +3 more
  • Lenexa, Kansas
    Pharmaceutical Research Associates, Inc.,
Jun 12, 2019

RSV Infection Trial in Lenexa (EDP-938, Cyclosporine, Prednisone)

Completed
  • RSV Infection
  • EDP-938
  • +2 more
  • Lenexa, Kansas
    Pharmaceutical Research Associates, Inc.,
Feb 10, 2019

RSV Infection Trial in Lenexa (EDP-938, Placebo)

Completed
  • RSV Infection
  • EDP-938
  • Placebo
  • Lenexa, Kansas
    Pharmaceutical Research Associates, Inc.,
Oct 9, 2018